Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Assets: 2011-2025

Historic Assets for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2025 value amounting to $18.4 million.

  • RedHill Biopharma's Assets fell 16.57% to $18.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.4 million, marking a year-over-year decrease of 16.57%. This contributed to the annual value of $18.0 million for FY2024, which is 21.71% down from last year.
  • According to the latest figures from Q2 2025, RedHill Biopharma's Assets is $18.4 million, which was up 1.84% from $18.0 million recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Assets registered a high of $220.1 million during Q1 2021, and its lowest value of $18.0 million during Q4 2024.
  • Its 3-year average for Assets is $29.2 million, with a median of $22.5 million in 2023.
  • Per our database at Business Quant, RedHill Biopharma's Assets soared by 53.42% in 2021 and then plummeted by 85.49% in 2023.
  • RedHill Biopharma's Assets (Quarterly) stood at $181.2 million in 2021, then declined by 12.32% to $158.9 million in 2022, then plummeted by 85.49% to $23.0 million in 2023, then dropped by 21.71% to $18.0 million in 2024, then declined by 16.57% to $18.4 million in 2025.
  • Its Assets stands at $18.4 million for Q2 2025, versus $18.0 million for Q4 2024 and $22.0 million for Q2 2024.